Atria Wealth Solutions Inc. Grows Stock Holdings in AstraZeneca PLC (NASDAQ:AZN)

Atria Wealth Solutions Inc. lifted its position in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) by 47.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 33,101 shares of the company's stock after purchasing an additional 10,647 shares during the quarter. Atria Wealth Solutions Inc.'s holdings in AstraZeneca were worth $2,229,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Anchor Investment Management LLC acquired a new stake in shares of AstraZeneca during the 4th quarter worth approximately $26,000. Compagnie Lombard Odier SCmA bought a new position in shares of AstraZeneca during the 4th quarter worth approximately $27,000. Nemes Rush Group LLC lifted its position in shares of AstraZeneca by 375.6% during the 3rd quarter. Nemes Rush Group LLC now owns 428 shares of the company's stock worth $29,000 after buying an additional 338 shares during the period. LWM Advisory Services LLC bought a new position in shares of AstraZeneca during the 3rd quarter worth approximately $35,000. Finally, Arlington Trust Co LLC bought a new position in shares of AstraZeneca during the 4th quarter worth approximately $37,000. Institutional investors and hedge funds own 20.35% of the company's stock.

Analyst Ratings Changes

AZN has been the subject of several research analyst reports. BMO Capital Markets lifted their price objective on AstraZeneca from $80.00 to $82.00 and gave the company an "outperform" rating in a research report on Friday. Morgan Stanley initiated coverage on AstraZeneca in a research report on Tuesday, January 23rd. They issued an "overweight" rating for the company. Jefferies Financial Group downgraded AstraZeneca from a "buy" rating to a "hold" rating in a research report on Wednesday, January 3rd. Finally, Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a "sell" rating to a "hold" rating in a research report on Tuesday, April 16th. Three research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, AstraZeneca currently has an average rating of "Moderate Buy" and a consensus target price of $81.00.

AstraZeneca Trading Up 0.5 %

Shares of AstraZeneca stock traded up $0.40 during trading on Tuesday, reaching $75.88. 8,547,254 shares of the company were exchanged, compared to its average volume of 6,273,296. The company has a quick ratio of 0.70, a current ratio of 0.89 and a debt-to-equity ratio of 0.73. AstraZeneca PLC has a twelve month low of $60.47 and a twelve month high of $76.58. The business has a 50-day moving average price of $67.71 and a 200-day moving average price of $66.16. The firm has a market capitalization of $235.26 billion, a price-to-earnings ratio of 37.20, a P/E/G ratio of 1.37 and a beta of 0.50.

AstraZeneca (NASDAQ:AZN - Get Free Report) last posted its earnings results on Thursday, February 8th. The company reported $0.73 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.74 by ($0.01). AstraZeneca had a net margin of 13.30% and a return on equity of 30.42%. The business had revenue of $12.02 billion during the quarter, compared to analyst estimates of $12.07 billion. During the same period in the previous year, the firm posted $0.69 earnings per share. The firm's revenue was up 7.3% on a year-over-year basis. Sell-side analysts anticipate that AstraZeneca PLC will post 4.01 EPS for the current fiscal year.

AstraZeneca Increases Dividend

The company also recently declared a Semi-Annual dividend, which was paid on Monday, March 25th. Stockholders of record on Friday, February 23rd were issued a $0.965 dividend. This represents a dividend yield of 2.3%. This is a positive change from AstraZeneca's previous Semi-Annual dividend of $0.47. The ex-dividend date of this dividend was Thursday, February 22nd. AstraZeneca's payout ratio is 94.61%.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.